cp wire

CP Wire Articles

Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
  • Tango will receive $50 million up front
  • The company could receive up to $1.7 billion in additional payments
  • The partnership will focus on building a pipeline of novel immuno... read more
Wed, 10/31/18 - 09:34 am
admin
CymaBay Initiates Ph III Study of Primary Biliary Cholangitis Drug
  • 1 in 1000 women over the age of 40 lives with PBC
  • The company also has clinical trials underway for NASH


CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced... read more

Tue, 10/30/18 - 10:23 am
admin
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients


 
Janssen Pharmaceutical today unveiled 96-week results from the pivotal Phase 3 AMBER study of Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide... read more

Tue, 10/30/18 - 09:53 am
admin
U.S. DOD Purchases Banyan Biomarkers' Brain Injury Blood Tests
  • Banyan BTI is the first test to aid in the diagnosis of concussion
  • The U.S. CDC estimates there are more than 2.5 million emergency room visits annually in the U.S. alone
... read more
Tue, 10/30/18 - 09:44 am
admin
Innovate Biopharmaceuticals Announces Promising Results of Larazotide in NASH Study
  • Larazotide is a tight junction regulator
  • The drug is also in Ph III trials for celiac disease
  • The FDA awarded fast track status to Larazotide for celiac
  • If approved... read more
Mon, 10/29/18 - 09:45 am
admin
Could Artificial Emotional Intelligence Platform Detect the First Signs of a Heart Attack?
  • Framework may also help protect dementia patients
  • One researcher attributes Watson's failure in cancer diagnosis to a lack of emotion in the data


BPU Holdings... read more

Mon, 10/29/18 - 09:17 am
admin
Opthea Reports Positive Data from Ph Ib Study for Diabetic Macular Edema Drug
  • A dose-response relationship of increased gains in visual acuity (VA) was shown with ascending dose levels of OPT-302
  • OPT-302 is also being studied in wet AMD patients

... read more

Fri, 10/26/18 - 09:52 am
admin
Galecto Biotech Books $89 Million in Series C Financing to Develop Fibrosis Candidate

Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing of a €79 million series... read more

Fri, 10/26/18 - 09:37 am
admin
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
  • Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional payments
  • Enterome and Takeda also have agreements targeting multiple other... read more
Thu, 10/25/18 - 12:41 pm
admin
Microbiome Report for Week Ending 10/20/18

LNC Therapeutics Acquires... read more

Thu, 10/25/18 - 11:39 am
admin
Neuralstem Rises on Publication of Alzheimer’s Stem Cell Therapy Data
  • The neural stem cell line into APP/PS1 mice that carry genes bearing mutations associated with onset of AD in humans
  • NSI-532.IGF1 is a second-generation cell therapy candidate that... read more
Thu, 10/25/18 - 09:48 am
admin
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
  • The FDA previously granted ruxolitinib Breakthrough Therapy Designation for the treatment of acute GVHD
  • Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi (... read more
Thu, 10/25/18 - 09:33 am
admin
FDA Approves First New Flu Drug in Nearly 20 Years
  • Xofluxa is a single-dose one-time treatment compared to Tamiflu's twice daily for five day regimen
  • In two trials, patients taking Xofluxa had a shorter duration of flu symptoms... read more
Wed, 10/24/18 - 12:39 pm
admin
Sponsored: Pharma Supply Chain and Quality Experts Can Stay on Top of Their Game at Temperature Controlled Logistics Event
The 18th Annual Temperature Controlled Logistics Conference will bring together supply chain, logistics and quality experts from around the globe to experience four days of ‘unmissable’... read more
Wed, 10/24/18 - 12:30 pm
admin
BeiGene Announces Acceptance of its NDA in China for Zanubrutinib in Certain Types of Leukemia and Lymphoma
  • Zanubrutinib demonstrated a high overall response rate of 80 percent
  • Zanubrutinib was recently granted Fast Track Designation by the US FDA for Waldenström macroglobulinemia (WM)... read more
Wed, 10/24/18 - 11:53 am
admin
Stelara Shines in Three Year Crohn's Disease Study
  • 60.3% of all randomised ustekinumab-treated patients who entered the long-term extension study were in clinical remission at week 152
  • Of those patients who were naïve to TNF... read more
Wed, 10/24/18 - 09:45 am
admin
Almac Diagnostic Services to Develop Companion Diagnostic for TP Therapeutics' Cancer Drug



TP Therapeutics announced on 10/24/18 a global collaboration agreement to develop and commercialize a next-generation sequencing (NGS) companion diagnostic (CDx) for repotrectinib, TP... read more

Wed, 10/24/18 - 09:30 am
admin
Bain Capital and Pfizer Create New Company Focused on CNS Disorders
  • Bain Capital committed $350 million to the company
  • Pfizer is contributing a portfolio of assets that includes three clinical-stage compounds


Bain Capital, LP and... read more

Tue, 10/23/18 - 10:14 am
admin
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
  • OMS721 also has orphan status for two other conditions
  • OMS721 is Omeros’ lead human MASP-2 antibody
  • The drug was awarded fast track designation for the treatment of patients... read more
Tue, 10/23/18 - 09:43 am
admin
FDA Accepts Xeris' Glucagon Rescue Pen NDA for Review
  • Glucagon is the standard of care for treating severe hypoglycemia
  • Mild to moderate hypoglycemia occurs monthly and severe hypoglycemia can occur several times per year
  • The... read more
Tue, 10/23/18 - 09:24 am
admin

Pages



current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.